Nodding Head Disease
A mysterious new disease is afflicting children in
Uganda, Sudan and Tanzania and has left health workers baffled. It
affects a tight age range of 5 to 15 years. Children begin to have head
nodding which occurs in clusters and is often precipitated by food and
cold weather. Affected children continue to slowly deteriorate, with
progressive cognitive decline and emaciation. They will often have frank
seizures. No one has recovered so far.
How do we look at a brand new disease? Is it
infectious? Are toxins involved? Why is there such strong temporal and
geographic clustering of an unusual and unexplained syndrome, consistent
with epilepsy? The CDC is assisting the South Sudan Ministry of Health
with its ongoing investigations. Proposed etiologies include infections,
nutritional, environmental, and psychogenic causes. Specific exposures
evaluated in previous studies include munitions, measles, monkey meat,
relief seeds, or relief food (e.g., lentils and sorghum). However all
investigations have drawn a blank. A case control study by the CDC has
shown a higher incidence of onchocerciasis, but the causal
pathophysiologic mechanism is not clear, and some have concluded that
the association is spurious. Although the cause of nodding syndrome
remains unknown, the CDC has recommended mass ivermectin treatment for
onchocerciasis and antiepileptic medication. But the jury is not out yet
about who or what is the culprit of this new syndrome (The Washington
Post 29 July, 2012, MMWR 27 Jan 2012).
First Man to be Cured of AIDS?
Timothy Ray Brown also known as "The Berlin Patient"
may go down in history as the first patient to be cured of AIDS. He was
first diagnosed to have AIDS in 1995. In 2007 while living in Germany he
underwent a stem cell transplant for AML. His donor had the CRR5 Ä32/Ä32
mutation. He has remained free of HIV and off antiretroviral drugs since
then despite a relapse of AML requiring a second successful transplant.
He has achieved immune reconstitution with adequate numbers of CD4 cells
in blood and gut mucosa with donor cells, without any evidence of HIV
virus replication. HIV RNA and DNA have not been detected in plasma and
other tissues.
This single patient study has generated intense
speculation and interest in both the academia and the hoi polloi. The
key is considered to be the CRR5 Ä32/Ä32 mutation. The CRR5 gene codes
for a protein which acts as a receptor for the HIV virus on CD4 cells.
Tim Brown received stem cells from a donor who was homozygous for a
mutation on the CRR5 gene which is known to confer immunity to primary
infection and slow disease progression in established HIV infection.
This gene is present in 1% of Europeans and arose sometime in the middle
ages and probably conferred some protection against the plague or small
pox.
It is hard to prove with certainty that HIV has been
fully eradicated from all its secret nooks and crannies. We are treading
new ground and how long without symptoms and without drugs means cure is
still to be defined. Stem cell therapy is invasive and expensive. Not
all HIV-infected patients who can live long, healthy lives with the use
of ART need it. Nor is it feasible to find HLA-matched donors with
Ä32/Ä32 mutation for the majority of people. Yet this study, the first
of its kind, provides a proof of concept for further evaluation of
strategies in the conquest of this quintessentially elusive virus (Blood
2011;117:2791-9).
Innovation Crisis in Drug Research
Two authoritative articles in the BMJ have slammed
the pharmaceutical industries constant harping of the so called
"innovation crisis in drug research". The authors argue that telling
"innovation crisis" stories to politicians and the press "serves as a
ploy to attract a range of government protections from free market
competition." Stories that the pipeline for new drugs will soon dry up
due to lack of government support are untenable. The number of new drugs
which debut each year continue steadily at a long term average of 15 –
25 a year. On the down side independent reviews have clearly shown that
85-90% of all new drugs in the past 50 years have provided few benefits
but considerable harm. Though the industry constantly harps at how much
it devotes to develop new drugs, the truth is that most of the money
goes in funding innumerable minor variations of a known drug which
brings in a steady stream of profits. Heavy promotion of these drugs can
account for up to 80% of a nation’s drug spending. According to an
independent analysis, the 1.3% of revenues devoted to discovering new
molecules compares with an estimated 25% spent on promotion, giving a
ratio of basic research to marketing of 1:19.
So, what can be done to change the business model of
the pharmaceutical industry to focus on more cost effective, safer
medicines. The first step should be to stop approving so many new drugs
of little therapeutic value. Drug manufacturers should have to show how
their products compare to existing treatments before approval. Raising
the evidence standards could also encourage manufacturers to concentrate
on the development of new drugs in therapeutic areas with few or no
alternatives (BMJ news 7 August 2012).